Nalaganje...
Long term use of bevacizumab in the treatment of triple negative breast cancer with giant tumor in chest wall: A case report
RATIONALE: Triple-negative breast cancer (TNBC) is associated with unfavorable prognosis due to lack of targeted agents. Bevacizumab, an anti-angiogenic monoclonal antibody against vascular endothelial growth factor A, has shown clinical effects in patients with TNBC. PATIENT CONCERNS: We reported a...
Shranjeno v:
| izdano v: | Medicine (Baltimore) |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Wolters Kluwer Health
2018
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6283199/ https://ncbi.nlm.nih.gov/pubmed/30508942 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000013410 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|